Volume 12, Number 11—November 2006
Dispatch
VEB-1 in Achromobacter xylosoxidans from Cystic Fibrosis Patient, France
Catherine Neuwirth*
, Carine Freby*, Agathe Ogier-Desserrey*, Stéphanie Perez-Martin*, Anne Houzel*, André Péchinot*, Jean-Marie Duez*, Fréderic Huet*, and Eliane Siebor*
, Carine Freby*, Agathe Ogier-Desserrey*, Stéphanie Perez-Martin*, Anne Houzel*, André Péchinot*, Jean-Marie Duez*, Fréderic Huet*, and Eliane Siebor*
Table 1
Beta-lactam MICs (μg/mL)
| β-lactams* | Achromobacter xylosoxidans AX476 | Escherichia coli K-12 C600 (pJDB1)† | E. coli K-12 C600‡ |
|---|---|---|---|
| Amoxicillin | 1,024 | 16 | 16 |
| Amoxicillin + CA | 32 | 2 | 8 |
| Ticarcillin | 256 | 64 | 8 |
| Ticarcillin + CA | 8 | 2 | 8 |
| Cefotaxime | >512 | 0.06 | 0.03 |
| Cefotaxime + CA | 256 | 0.03 | 0.03 |
| Ceftazidime | 512 | 2 | 0.125 |
| Ceftazidime + CA | 16 | 0.125 | 0.125 |
| Aztreonam | >512 | 4 | 0.125 |
| Aztreonal + CA | 256 | 0.125 | 0.125 |
| Cefepime | 512 | 0.06 | 0.03 |
| Cefepime + CA | 128 | 0.03 | 0.03
*CA, clavulanic acid, used at 2 μg/mL. |
*CA, clavulanic acid, used at 2 μg/mL.
†Transconjugant.
‡Reference strain.
Page created: October 14, 2011
Page updated: October 14, 2011
Page reviewed: October 14, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.